Impact of prediabetes and duration of diabetes on radial artery atherosclerosis in acute coronary syndrome patients: An optical coherence tomography study

Zixuan Li¹, Zhe Tang², Yujie Wang¹, Zijing Liu¹, Senhu Wang¹, Yuntao Wang¹, Guozhong Wang¹, Yuping Wang¹ and Jincheng Guo¹

Abstract
Background: Prediabetes (PDM) and diabetes mellitus (DM) are common among acute coronary syndrome (ACS) patients. The present study evaluated the association between diabetes status and radial artery (RA) atherosclerosis using optical coherence tomography (OCT) in ACS patients.
Methods: A total of 335 ACS patients who underwent RA OCT were categorized into the DM group, the PDM group, and the normal glucose metabolism (NGM) group. OCT characteristics and clinical variables were compared.
Results: RA atherosclerotic plaques were more frequent in the PDM and DM groups than in the NGM group (38.7% vs. 33.3% vs. 16.1%, \( p = 0.001 \)). Lipid and calcified plaque occurrence were significantly more common in the DM group, followed by the PDM and NGM groups (19.3% vs. 14.6% vs. 6.5%, \( p = 0.027 \); 11.8% vs. 6.5% vs. 1.1%, \( p = 0.009 \)). The prevalence of microvessels in the PDM group was significantly higher (42.7% vs 23.7%, \( p = 0.017 \)) than in the NGM group but was comparable to the DM group. Multivariate analysis revealed that HbA1c level and age were independent predictors of RA plaque formation and eccentric intimal hyperplasia (all \( p < 0.05 \)).
Conclusions: RA atherosclerosis characteristics differ according to diabetes status. HbA1c level could be a useful marker for RA atherosclerosis progression in ACS patients.

Keywords
Diabetes, prediabetes, optical coherence tomography, acute coronary syndrome, radial artery atherosclerosis

Key messages
- Patients with DM and PDM were more likely to have RA atherosclerosis than those with normal glucose levels.
- RA OCT characteristics differ according to glycemic status.
- HbA1c level may be a useful marker for RA atherosclerosis progression in patients with ACS.

Introduction
Cardiovascular disease is the leading cause of death in patients with diabetes mellitus (DM), and approximately one-fourth of patients who develop acute coronary syndrome (ACS) have DM.³ Coronary artery bypass grafting (CABG) has been demonstrated to improve long-term

¹Department of Cardiology, Beijing Luhe Hospital, Capital Medical University, Beijing, China
²Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China

Corresponding author: Jincheng Guo, Department of Cardiology, Beijing Luhe Hospital, Capital Medical University, No.82, Xinhua South Road, Tongzhou District, Beijing 101149, China. Email: guojcmd@126.com
outcomes after ACS in DM patients with multivessel coronary disease. The radial artery (RA) is considered as a second arterial conduit for CABG due to its efficacy and safety. However, previous studies demonstrated that radial arteries are associated with some degree of atherosclerosis which may have a detrimental effect on graft patency or render them unsuitable as a graft in CABG. Although DM is a known risk factor for silent RA atherosclerosis, the incidence of RA atherosclerosis in patients with DM has not been widely investigated. Several methods have been used to evaluate RA atherosclerosis including ultrasonography, intravascular ultrasound (IVUS), and harvested radial artery pathology, but their role in detecting atherosclerosis is limited by their poor spatial resolution or presence of pathology in the discarded distal segments of the RA.

Optical coherence tomography (OCT) is a high-resolution imaging technique that has been well established for evaluating vulnerable coronary plaques in patients with ACS. Its utility for the evaluation of RA atherosclerotic plaque was confirmed by a previous validation study in which RA atherosclerotic plaque components and tissue layers were identified by OCT and which reported high agreement with histological results.

In this study, we compared RA atherosclerosis among diabetic and non-diabetic patients with ACS using OCT. We also investigated whether DM duration had any negative effects on plaque characteristics in diabetic ACS patients.

**Methods**

**Patient population**

A total of 462 consecutive patients with ACS who underwent RA OCT after coronary OCT at our institute between March 2019 and December 2020 were enrolled in the present study. The study flowchart is shown in Figure 1. Clinical data such as age, sex, and classic risk factors for atherosclerosis were collected. The study population was stratified according to three glycemic categories in accordance with the definition by the American Diabetes Association: DM group [(self-reported type 2 DM, hemoglobin A1c (HbA1c) >6.4% (47 mmol/mol), and/or use of insulin)], prediabetes group [(PDM, no self-reported type 2 DM and HbA1c of 5.7%–6.4% (39–47 mmol/mol)], and normoglycemia group [NGM, no self-reported type 2 DM and HbA1c < 5.7% (39 mmol/mol)]. The HbA1c levels in whole blood were routinely measured in all patients using high-performance liquid chromatography with ELUENT 80A (ARKRAY, IN, Japan). Patients with type 2 DM were further divided into two subgroups: long-DM group (DM duration ≥10 years) and short-DM group (DM duration <10 years). All laboratory data were collected during fasting throughout the hospitalization period. Written informed consent was obtained from all the patients. This study was performed in accordance with the Declaration of Helsinki and was approved by the ethics committee of the Beijing Luhe Hospital, Capital Medical University (Beijing, China).

**OCT image acquisition**

After a 6F sheath (Terumo Co, Tokyo, Japan) was inserted at the default vascular access of the right RA, coronary angiography and percutaneous coronary intervention were performed with 6 Fr catheters. Upon completion of the coronary procedure, the protocol described below (Figure 2) was implemented to perform OCT imaging of the RA. Three OCT pullback recordings (20 mm/s) including proximal (0–50 mm), middle (50–100 mm), and distal (100–150 mm) portions were acquired using saline to flush the RA. The OCT procedure was performed using a C7XR FD-OCT system (St. Paul, MN, USA).

![Figure 1. Study flowchart.](image1)

![Figure 2. Algorithm for radial artery OCT imaging. OCT = optical coherence tomography; RA = radial artery; RAA = radial artery angiography.](image2)
**OCT image interpretation**

The OCT image analysis was performed using proprietary software (LightLab Imaging), and the correct calibration settings for Z-offset were confirmed by two independent and experienced readers (TZ, LZX) who were unaware of the clinical data.

The RA imaging characteristics were based on the current OCT consensus standard. In this study, atherosclerotic plaques were defined and classified into three categories: (1) fibrous plaques were defined by a homogeneous signal and high backscattering region; (2) lipid plaques were defined by a low-signal region with a diffuse border; and (3) calcified plaques were defined as a plaque containing calcium deposits (signal-poor regions with sharply delineated borders). Representative images are shown in Figure 3. The longitudinal length of each plaque was assessed, and two plaques were seen as separated when their distance was more than 10 mm in the longitudinal view. For lipid plaques, the fibrous cap thickness (FCT) and maximal lipid arc were measured three times at the thinnest part, and the average value was calculated. When lipid deposits were present at $\geq 90$ in any of the cross-sectional images within the plaque, it was considered a lipid-rich plaque. A TCFA was defined as an FCT thickness of $\leq 65$ $\mu m$ in a lipid-rich plaque on cross-sectional imaging. Calcium deposits were analyzed individually by measuring calcium longitudinal length, arc, and depth. The maximum calcium arc, maximal depth, and FCT of the calcific plaques were analyzed. Spotty calcification was defined plaques with a length of $<4$ mm and a maximal arc of $<90^\circ$. Microvessels were defined as black holes with diameters of 50–300 $\mu m$ that were sharply delineated for at least three consecutive frames. Macrophage infiltration was defined as signal-rich, distinct, or confluent punctuate regions that exceed the intensity of background speckle noise. The severity of intimal hyperplasia in RA has been reported previously (Supplemental Methods).

**Reproducibility of qualitative OCT assessment**

An author (TZ) who was blinded to clinical, angiographic, and OCT data selected 50 cases after all annotations on OCT images were deleted. For the inter-observer variability assessment, two experienced OCT observers (LZX and TZ) interpreted the 50 OCT cases, and then an OCT observer (LZX) assessed them again at 4-week intervals. The inter- and intra-observer kappa coefficients for the plaque presence and plaque phenotypes were 0.919–0.975.

**Statistical analysis**

Statistical analysis was performed using SPSS (version 23.0; IBM Corp., Armonk, New York). Categorical variables were expressed as numbers (percentages). Continuous
variables were presented as mean ± standard deviation. The normality of variables was assessed using the Shapiro–Wilk test. Categorical variables were compared using the χ² test. Continuous variables were compared using the Mann–Whitney U test, one-way analysis of variance (ANOVA), or Kruskal–Wallis ANOVA on ranks as appropriate. Further multiple comparison analysis was performed to analyze within-group differences; the post-hoc Scheffé method was chosen for continuous data, and the Bonferroni method for categorical data. The association between RA plaque presence and traditional risk factors or biochemical biomarkers was assessed using multivariate analysis. All variables with p < 0.1 in univariable analysis were entered en bloc in the multivariable model. Variables with significant contribution to the regression model were kept in the combination models and were plotted with a receiver-operating characteristic (ROC) curve. A two-tailed p value of <0.05 was considered statistically significant.

Results

Study populations and baseline characteristics

The patient characteristics are summarized in Table 1. Of the enrolled patients, 119 (35.5%) had DM, 123 (36.7%) had PDM, and 93 (27.8%) had normoglycemia. Patients with DM were older, more likely to be female, had a higher prevalence of hypertension and higher body mass index, and had higher estimated glomerular filtration rate (eGFR) and fasting plasma glucose level. However, other risk factors were equally distributed among the three groups. Among the 119 patients with DM, 42 were newly diagnosed at admission. Concerning antihyperglycemic therapies, 18 patients were treated with insulin, 55 with oral agents, and 8 with diet modification alone.

OCT findings

A comparison of the OCT findings among the three groups is shown in Table 2. In patient-level analysis, RA plaques were more prevalent in patients with DM and PDM than in those with NGM (38.7% vs. 33.3% vs. 16.1%, p = 0.001). The DM and PDM groups demonstrated higher plaque numbers per patient than the NGM group (2.26±1.06 and 1.88±1.12 vs. 1.50±0.82, p = 0.035). The proportion of RA lipid plaques was significantly lower in the NGM group than in the DM group (19.3% vs. 6.5%, p = 0.007). However, patients in the DM group had fewer lipid plaques than those in the PDM group, with a borderline significance (14.6% vs. 6.5%, p = 0.058). Calcified plaques were only detected in one patient in the NGM group (1.1%), whereas the incidence of calcified plaques was comparable between the DM and PDM groups (11.8% and 6.5%, respectively; p = 0.155). In particular, calcified plaques were prone to cluster distally in the RA of DM patients (10.1%). There were no significant differences in fibrous plaques among the three groups. In addition, the percentage of microvessels was significantly higher in the DM group (42.7% vs. 23.7%, p = 0.002) and PDM groups (39.0% vs. 23.7%, p = 0.017) than in the NGM group.

Among DM patients, the frequency of the three plaque phenotypes and macrophage presence was higher in the long-DM group than in the short-DM group (all p < 0.05) (Table 3).

In plaque-level analysis, a total of 205 RA plaques were detected in 102 cases (24 plaques in 15 NGM subjects, 77 plaques in 41 PDM subjects, and 104 plaques in 46 DM subjects). A comparison of the quantitative OCT findings at the plaque level among the three groups is presented in Supplementary Table 1.

As shown in Table 2 and Supplementary Table 2, compared with the NGM group, the DM and PDM groups showed a significant increase in intima-media ratio (IMR), maximum intimal thickness (MIT), intimal eccentricity index (IEI), and intimal area (all p < 0.05). The proportion of crescent-shaped intimal hyperplasia was the highest in diabetic patients, followed by that in prediabetic and NGM patients, respectively (21.8% vs. 15.4% vs. 8.6%, p = 0.032).

Multivariate analysis of risk factors for RA plaque formation

The findings of univariate and multivariate logistic regression analyses using RA plaque presence as the dependent variable are shown in Table 4 and Supplementary Table 4. All the variables in univariate logistic regression analysis with p < 0.1 were entered en bloc in the multivariable model, including age, sex, hypertension, eGFR, triglyceride levels, prior antiplatelet and history of statin use. Multivariate analysis showed that HbA1c level and age were identified as independent risk factors for RA plaque formation (all p < 0.05). The area under the ROC curve of HbA1c and age for RA plaque presence was 0.779 (95% CI 0.727–0.832, p < 0.001), with sensitivity and specificity of 71.6% and 65.1%, respectively (Figure 4). Longer duration (≥10 years) and age were independent risk factors for RA plaque in patients with DM (Table 4 and Supplementary Table 3).

Multivariate linear regression analysis showed that HbA1c level was the only independent predictor of IEI after controlling for age (Table 5 and Supplementary Table 5).

Discussion

In the present study, OCT, a novel high-resolution technique with a spatial resolution of 10 μm, demonstrated that atherosclerotic plaque presence and the extent of intimal hyperplasia of the RA in the PDM group were greater than...
### Table 1. Baseline patient characteristics.

| Variable                  | Overall (n = 335) | NGM (n = 93) | PDM (n = 123) | DM (n = 119) | P value |
|---------------------------|-------------------|--------------|---------------|--------------|---------|
| Age, years                | 57.47±13.20       | 53.55±13.12  | 58.9±13.47    | 59.08±12.43  | 0.003   |
| Male                      | 264 (78.8)        | 78 (83.9)c   | 101 (82.1)    | 85 (71.4)b   | 0.047   |
| BMI, kg/m²                | 26.22±3.41        | 25.42±3.45   | 26.49±3.44    | 26.56±3.26b  | 0.029   |
| Smoking                   | 221 (66.0)        | 69 (74.2)    | 81 (65.9)     | 71 (59.7)    | 0.086   |
| Hypertension              | 179 (53.4)        | 39 (41.9)    | 64 (52.0)     | 76 (63.9)b   | 0.006   |
| Hyperlipidemia            | 194 (62.0)        | 50 (55.6)    | 73 (64.6)     | 71 (64.5)    | 0.331   |
| PVD                       | 9 (2.7)           | 2 (2.2)      | 2 (1.6)       | 5 (4.2)      | 0.444   |
| Renal insufficiency       | 18 (5.4)          | 3 (3.2)      | 7 (5.7)       | 8 (6.7)      | 0.497   |
| Prior stroke              | 22 (6.6)          | 7 (7.5)      | 6 (4.9)       | 9 (7.6)      | 0.636   |
| Prior MI                  | 3 (0.9)           | 1 (1.1)      | 0             | 2 (1.7)      | 0.386   |
| CAD family history        | 43 (12.8)         | 11 (11.8)    | 16 (13.0)     | 16 (13.4)    | 0.938   |
| Biochemistry data         |                   |              |               |              | 0.266   |
| HbA1c, %                  | 6.66±1.80         | 5.42±0.02    | 5.96±0.02a    | 8.34±0.20b,c | <0.001  |
| Fasting glucose, mmol/L   | 6.00 (5.17±7.60)  | 5.14 (4.69±5.80) | 5.75 (5.24±6.5)a | 8.39 (6.45±10.74)b,c | <0.001  |
| Triglycerides, mg/dL      | 150.43±116.06     | 138.89±96.35 | 138.95±71.39  | 171.32±157.91 | 0.050   |
| TC, mg/dL                 | 177.40±41.48      | 172.82±41.57 | 183.23±41.60  | 174.95±40.93 | 0.137   |
| LDL-C, mg/dL              | 116.85±34.32      | 115.13±36.53 | 121.10±34.46  | 113.79±32.17 | 0.216   |
| HDL-C, mg/dL              | 42.42±13.17       | 43.7±2.12    | 42.08±8.31    | 41.78±9.51   | 0.536   |
| Lipoprotein (a), mg/L     | 125 (68-261)      | 109 (71,247) | 132 (71,285)  | 126 (56,245) | 0.706   |
| Creatinine, mmol/L        | 75.79±15.88       | 75.41±15.62  | 77.61±15.02   | 74.70±16.87  | 0.240   |
| eGFR, mL/min/1.73 m²      | 91.77±17.41a      | 95.50±17.49  | 89.70±16.52   | 90.99±17.92  | 0.044   |
| Hemoglobin, g/L           | 141.33±15.96      | 142.36±17.59 | 140.52±14.32  | 141.37±16.32 | 0.704   |
| **Procedures**            |                   |              |               |              | 0.308   |
| CAG                       | 29 (8.7)          | 11 (11.8)    | 11 (8.9)      | 7 (5.9)      |         |
| PCI                       | 306 (91.3)        | 82 (88.2)    | 112 (91.1)    | 112 (94.1)   |         |
| Procedure time, min       | 78.1±28.65        | 75.40±22.91  | 80.52±31.16   | 77.73±29.98  | 0.424   |
| Volume of CM, mL          | 203.18±69.88      | 200.69±55.25 | 204.62±72.02  | 203.64±77.93 | 0.917   |
| Prior medications         |                   |              |               |              |         |
| Antiplatelet              | 13 (3.9)          | 3 (3.2)      | 4 (3.3)       | 6 (5.0)      | 0.772   |
| Statin                    | 16 (4.8)          | 3 (3.2)      | 4 (3.3)       | 9 (7.6)      | 0.224   |
| CCB                       | 71 (21.2)         | 18 (19.4)    | 23 (18.7)     | 30 (25.2)    | 0.407   |

(continued)
Table 1. (continued)

| Variable          | Overall (n = 335) | NGM (n = 93) | PDM (n = 123) | DM (n = 119) | P value |
|-------------------|-------------------|-------------|--------------|--------------|---------|
| Beta blocker      | 22 (6.6)          | 3 (3.2)     | 8 (6.5)      | 11 (9.2)     | 0.214   |
| ACEI/ARB          | 44 (13.1)         | 11 (11.8)   | 14 (11.4)    | 19 (16.0)    | 0.520   |
| Insulin           |                   |             |              |              |         |
| Oral agents       | 47 (39.5)         |             |              |              |         |
| Diet only         | 8 (6.7)           |             |              |              |         |
| Newly diagnosed DM| 42 (12.5)         |             |              |              |         |
| Duration of DM    | 7.58±5.81         |             |              |              |         |
| Short (<10 years) | 78                |             |              |              |         |
| Long (≥10 years)  | 41                |             |              |              |         |

Data are shown as mean± standard deviation, number (%), or median (interquartile range).

ACE = angiotensin-converting enzyme; ARB = angiotensin II receptor blocker; CAD = coronary artery disease; CAG = coronary angiogram; CCB = calcium channel blocker; DM = diabetes mellitus; HDL-C = high-density lipoprotein cholesterol; LDL = low-density lipoprotein; MI = myocardial infarction; NGM = normoglycemia; PDM = prediabetes; PCI = percutaneous coronary intervention; renal insufficiency = estimated glomerular filtration <60 mL/min/1.73 m²; VD = vessel disease; SD = standard deviation.

P<0.05 for:

aNGM group versus PDM group.

bNGM group versus DM group.

cPDM group versus DM group.
Those in the NGM group but comparable to those in the DM group. HbA1c levels increase in advanced atherosclerosis and can help identify at-risk individuals. Moreover, individuals with a longer duration of DM showed a higher prevalence of RA plaque phenotypes and macrophage presence. These data suggest that even prediabetic status affects the microstructure of the RA; meanwhile, a longer duration of DM will further aggravate atherosclerosis.

Evidence suggests that patients with DM have accelerated vascular atherosclerosis that affects multiple vessels, and prolonged exposure to high levels of glucose can alter systemic endothelial function. In line with previous studies, DM was identified as a risk factor for RA intimal hyperplasia or atherosclerosis. Electron microscopic comparisons of distal RA grafts obtained from diabetic patients have previously shown an increase in histological changes, such as endothelial cell damage, compared to grafts from non-diabetic patients, especially those with long-standing duration or poor glycemic control. Recent studies have reported that patients with PDM have a higher prevalence of subclinical atherosclerosis. Thus, our study raises the question of the subclinical status of RA structural changes that occur before and after the diagnosis of DM. Structures such as arterial layers and plaque components of the RA are often difficult to visualize in vivo and are easily evaluated by OCT after routine coronary procedures.

Prior work has documented that preoperative quality evaluation of RA grafts is crucial for their long-term patency. For example, ultrasound and histopathologic studies have demonstrated that RAs in diabetic patients were more prone to calcium deposition, which may make the RA an unusable conduit in many of these patients. Brown et al. confirmed that intraoperative OCT imaging of RAs that were considered as acceptable for bypass grafting allowed for detection of intimal lipids which could

### Table 2. Optical coherence tomography features of the RA stratified according to glycemic status.

| Variable                      | Total          | NGM (n = 93) | PDM (n = 123) | DM (n = 119) | p value |
|-------------------------------|----------------|--------------|---------------|--------------|---------|
| RA length, mm                 | 171.98±16.90   | 172.10±16.59 | 172.95±16.58  | 170.89±17.54 | 0.641   |
| ≥1 Plaque                     | 102 (30.4)     | 15 (16.1)    | 41 (33.3)     | 46 (38.7)    | 0.001   |
| Plaques number per patient    | 1.99±1.08      | 1.50±0.82    | 1.88±1.12     | 2.26±1.06    | 0.035   |
| Total plaque length           | 8.05 (4.35–17.73) | 6.6 (3.3–9.6) | 7.4 (2.95–14.65) | 8.95 (4.80–32.45) | 0.151   |
| Plaque location                |                |              |               |              |         |
| Proximal                      | 59 (17.6)      | 7 (7.5)      | 22 (17.9)     | 30 (25.2)    | 0.004   |
| Middle                        | 42 (12.5)      | 6 (6.5)      | 6 (13.0)      | 20 (16.8)    | 0.076   |
| Distal                        | 71 (21.2)      | 9 (9.7)      | 26 (21.1)     | 36 (30.3)    | 0.001   |
| Fibrous plaque                | 68 (20.3)      | 11 (11.8)    | 28 (22.8)     | 29 (24.4)    | 0.055   |
| Total length                  | 5.30 (2.73–9.40) | 4.9 (3.0–9.6) | 5.20 (2.18–7.95) | 5.6 (2.8–17.65) | 0.564   |
| Lipid plaque                  | 47 (14.0)      | 6 (6.5)      | 18 (14.6)     | 23 (19.3)    | 0.027   |
| Total length                  | 5.60 (3.20–10.80) | 5.05 (2.68–8.55) | 5.7 (4.4–14.3) | 4.8 (3.2–10.8) | 0.504   |
| Calcified plaque              | 23 (6.9)       | 1 (1.1)      | 8 (6.5)       | 14 (11.8)    | 0.009   |
| Total length                  | 9.8 (5.9–35.0) | 2.9          | 9.05 (6.50–47.95) | 10.70 (4.83–39.83) | 0.375   |
| Micro vessels                 | 122 (36.4)     | 22 (23.7)    | 48 (39.0)     | 52 (42.7)    | 0.008   |
| Macrophages                   | 43 (12.8)      | 8 (8.6)      | 15 (12.2)     | 20 (16.8)    | 0.201   |
| RA structures                 |                |              |               |              |         |
| Lumen area, mm²               | 6.22 (5.00–8.00) | 6.15 (4.52–7.78) | 6.58 (5.11–8.13) | 5.94 (4.90–8.11) | 0.332   |
| Diameter, mm                  | 2.80 (2.52–3.18) | 2.78 (2.43–3.11) | 2.86 (2.54–3.21) | 2.75 (2.52–3.21) | 0.242   |
| Maximal intimal thickness, mm | 0.13 (0.08–0.17) | 0.10 (0.06–0.11) | 0.13 (0.08–0.18) | 0.15 (0.10–0.19) | <0.001 |
| IMR                           | 0.90 (0.53–1.40) | 0.75 (0.37–1.20) | 0.91 (0.53–1.27) | 1.10 (0.65–1.63) | 0.001   |
| IEI                           | 2.65 (1.87–3.25) | 2.19 (1.67–2.92) | 2.72 (1.83–3.24) | 2.84 (2.17–3.44) | <0.001 |
| ITI                           | 0.46 (0.37–0.57) | 0.43 (0.36–0.50) | 0.46 (0.37–0.58) | 0.49 (0.38–0.60) | 0.217   |
| LN, %                         | 26.95 (23.92–30.45) | 26.11 (23.48–29.67) | 27.26 (24.22–30.39) | 27.56 (23.92–31.32) | 0.622   |
| Intima area, mm²              | 0.72 (0.55–0.93) | 0.63 (0.49–0.85) | 0.74 (0.58–0.95) | 0.76 (0.59–0.96) | 0.005   |
| Media area, mm²               | 1.60 (1.32–1.91) | 1.54 (1.23–1.92) | 1.64 (1.36–1.91) | 1.62 (1.36–1.91) | 0.790   |
| Crescent-shaped intimal hyperplasia | 53 (15.8)     | 8 (8.6)      | 19 (15.4)     | 26 (21.8)    | 0.032   |

| IMR = intima-media ratio; IEI = intimal eccentricity index; ITI = intimal thickness index; LN = luminal narrowing. |
| Distance from RA ostium to puncture site; |
| b = p < 0.05 for NGM group versus PDM group; |
| c = p < 0.05 for NGM group versus DM group. |
help predict the degree of postoperative spasm of the RA. Importantly, the current OCT observation expands this understanding; we found a significantly higher incidence of RA plaque presence in both the DM and PDM groups than in the NGM group, and the incidence of RA lipid plaque was significantly higher in the DM group, followed by that in the PDM and NGM groups. Given the complex abnormalities of vascular complications seen in DM patients, it is not surprising that percutaneous or surgical coronary revascularization after ACS is less effective in diabetic than in non-diabetic patients.27-29

Jared et al. reported that the durations of DM and PDM during adulthood are both independently associated with subclinical atherosclerosis in middle-aged patients.30 In the present study, patients with long-standing DM had higher levels of RA atherosclerotic alterations, including plaque phenotype and macrophage presence, which may aggravate its impaired vasoreactivity.11 These findings add to the relationship between HbA1c level, disease duration, and diabetic atherosclerosis progression in ACS patients, which

| Variable                              | DM duration <10 years (n = 78) | DM duration ≥10 years (n = 41) | p value |
|---------------------------------------|--------------------------------|--------------------------------|---------|
| Presence of plaque                    | 21(26.9)                       | 25(61.0)                       | <0.001  |
| Plaque site                           |                                |                                |         |
| Proximal                              | 13(16.7)                       | 17(41.5)                       | 0.003   |
| Middle                                | 7(9.0)                         | 13(31.7)                       | 0.002   |
| Distal                                | 15(19.2)                       | 21(51.2)                       | <0.001  |
| Total length                          | 7.90(4.80–13.30)               | 13.10(4.80–36.65)              | 0.270   |
| Fibrous                               | 14(17.9)                       | 15(36.6)                       | 0.024   |
| Total length                          | 4.9(2.85–8.65)                 | 6.60(2.30–26.50)               | 0.541   |
| Lipid                                 | 10(12.8)                       | 13(31.7)                       | 0.013   |
| Total length                          | 4.85(3.05–14.45)               | 4.80(2.90–11.60)               | 0.877   |
| Calcification                         | 5(6.4)                         | 9(22.0)                        | 0.028   |
| Total length                          | 10.10(6.10–51.45)              | 13.40(5.65–44.65)              | 0.841   |
| Micro vessels                         | 32(41.0)                       | 20(48.8)                       | 0.418   |
| Macrophages                           | 9(11.5)                        | 11(26.8)                       | 0.034   |
| Crescent-shaped intimal hyperplasia   | 18(23.1)                       | 8(19.5)                        | 0.655   |

| Variable                              | Univariate analysis            | Multivariate analysis         |
|---------------------------------------|--------------------------------|-------------------------------|
|                                       | p value | OR    | 95%CI          | p value | OR    | 95%CI          |
| For Total a                           |         |       |                |         |       |                |
| Age, years                            | <0.001  | 1.086 | 1.061–1.111    | <0.001  | 1.087 | 1.053–1.122    |
| HbA1c, %                              | 0.029   | 1.148 | 1.014–1.299    | 0.007   | 1.221 | 1.056–1.411    |
| For DM b                             |         |       |                |         |       |                |
| Age, years                            | <0.001  | 1.093 | 1.050–1.137    | <0.001  | 1.099 | 1.043–1.159    |
| DM Duration (long vs. short)          | <0.001  | 4.241 | 1.901–9.463    | 0.005   | 3.752 | 1.502–9.369    |

*adjustment for age, sex, hypertension, eGFR, HbA1c, triglycerides, statin, and antiplatelet.

*adjustment for age, DM duration, eGFR, hypertension, and triglycerides.

![Figure 4. Receiver-operating characteristic curves of HbA1c combined with age for predicting RA plaque presence.](image-url)
helps to understand the structural alterations of the vascular tree in patients with DM.

Pathologic studies revealed that coronary tissue from patients with DM exhibited more microstructure than that from patients without DM. Microvessels are focally enhanced in areas of increased vessel wall thickness, and atherosclerotic lesion formation typically precedes the appearance of endothelial dysfunction. Consistently, we found a significant increasing trend in RA microvessel presence among patients with NGM, PDM, and DM. Furthermore, macrophage accumulation was more common in patients with longer DM duration, which has been reported to play an important role during various steps of atherosclerosis and promote ACS events, thus indicating a higher level of plaque vulnerability.

HbA1c is not only a useful biomarker of long-term glycemic control but also a good predictor of atherosclerosis. For example, Shah et al. reported that a 1% increase in HbA1c is associated with an approximately 30% increase in probability of a thicker carotid IMT. Recently, Rossello et al. demonstrated a linear association between HbA1c > 5.4% level and multi-territory subclinical atherosclerosis detected by vascular ultrasound and non-contrast cardiac CT in carotid arteries, coronary arteries, and peripheral arteries in non-diabetic individuals. In the present study, we found an obvious intimal hyperplasia of the RA in the DM and PDM groups but not in the NGM group, and the intimal eccentric index was positively associated with HbA1c level. These findings extend previous research on the effect of HbA1c and highlight the association between HbA1c and RA atherosclerosis.

Data obtained in previous studies using a high-frequency ultrasound (55 Hz) indicated that assessment of RA intima thickness, other than RA media thickness, provides a tool for non-invasive early detection of atherosclerosis or additive value for the diagnosis of coronary artery disease. Although IVUS has been used to quantify RA atheroma burden, it cannot reliably identify the separation between the intima and media because of its limited spatial resolution. In our study, the use of OCT allowed for the evaluation of even slight metabolic changes which contribute to the microstructural phenotype changes of the RA. The potential of RA intimal hyperplasia or plaque components that considered as cardiovascular risk modifiers deserve further investigation in future studies.

**Study limitations**

The present study had some limitations. First, this was a retrospective observational study from a single-center database; therefore, selection bias may have influenced the results. Second, we could not confirm that the effects of anti-atherosclerotic drugs, such as statins and hypoglycemic agents, were not independently associated with plaque regression. Recent studies have demonstrated that statin therapy increases FCT, thereby stabilizing the plaque irrespective of the DM status. Third, the lack of longitudinal follow-up data did not allow for assessment of the clinical impact of OCT findings on future events. Fourth, in the present study, although it is hypothesized that the region of crescent-shaped intimal hyperplasia is prone to plaque formation, these data were not examined. Fifth, the RA is a good candidate for OCT imaging owing to its diameter; however, OCT is an invasive method used in the research stage and its role in clinical applications has not been fully established. In the present study, OCT imaging of the RA required little additional effort after the completion of the coronary OCT procedure during transradial intervention. In addition, to avoid wire artifacts, when the OCT catheter was in place, the guide wire was removed from the body. In the future, non-invasive and very high-resolution ultrasound is needed to evaluate RA atherosclerosis in clinical scenarios.

**Conclusions**

PDM stratified by HbA1c level is associated with RA plaque characteristics and eccentric intimal hyperplasia in

| Variable | Univariate analysis | Multivariate analysis |
|----------|---------------------|----------------------|
|          | β                   | p Value              | 95% CI for β | β       | p Value              | 95% CI for β |
| IEI      |                     |                      |             |        |                      |             |
| Age, years | 0.031               | <0.001              | 0.024–0.039 | 0.413   | <0.001              | 0.024–0.039 |
| HbA1c, % | 0.143               | 0.009               | 0.020–0.138 | 0.135   | 0.007               | 0.021–0.128 |
| IMR      |                     |                      |             |        |                      |             |
| Age, years | 0.541               | <0.001              | 0.024–0.034 | 0.491   | <0.001              | 0.021–0.032 |
| Sex      | –0.317              | <0.001              | –0.731–0.375| –0.131  | 0.009               | –0.397–0.058 |

*a adjustment for sex, smoker, BMI, eGFR, hypertension, familial history of CAD, lipid levels, cholesterol, and medications.

*b adjustment for smoker, BMI, eGFR, HbA1c, hypertension, familial history of CAD, lipid levels, cholesterol, and medications.
ACS patients, similar to DM. HbA1c level could be a useful marker for RA atherosclerosis progression. Moreover, DM with a longer duration contributed to more damage to RA. This study highlighted that the prevention of vascular complications started below the threshold for DM, and the RA in patients with extended DM duration requires more attention.

Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by grant No.2018-2-7082 from the Capital’s Funds for Health Improvement and Research, and grant No.2020CX004-15 from the TongZhou District Funds.

ORCID iD
Zixuan Li https://orcid.org/0000-0002-5324-6966

Supplemental material
Supplemental material for this article is available online.

References
1. Farkouh ME, Domanski M, Dangas GD, et al. Long-term survival following multivessel revascularization in patients with diabetes: The FREEDOM follow-on study. J Am Coll Cardiol 2019; 73: 629–638.
2. Godoy LC, Tavares CAM and Farkouh ME. Weighing coronary revascularization options in patients with type 2 diabetes mellitus. Can J Diabetes 2020; 44: 78–85.
3. Godoy LC, Rao V and Farkouh ME. Coronary revascularization of patients with diabetes mellitus in the setting of acute coronary syndromes. Circulation 2019; 140: 1233–1235.
4. Ramanathan K, Abel JG, Park JE, et al. Surgical versus percutaneous coronary revascularization in patients with diabetes and acute coronary syndromes. J Am Coll Cardiol 2017; 70: 2995–3006.
5. Gaudino M, Benedetto U, Fresmes S, et al. Association of radial artery graft vs saphenous vein graft with long-term cardiovascular outcomes among patients undergoing coronary artery bypass grafting: A systematic review and meta-analysis. JAMA 2020; 324: 179–187.
6. Ruengsakulrach P, Sinclair R, Komeda M, et al. Comparative histopathology of radial artery versus internal thoracic artery and risk factors for development of intimal hyperplasia and atherosclerosis. Circulation 1999; 100: III39–44.
7. Timica G, Vartic CL, Mocanu V, et al. Preoperative graft assessment in aortocoronary bypass surgery. Exp Ther Med 2016; 12: 804–808.
8. Gaudino M, Antoniades C, Benedetto U, et al. Mechanisms, consequences, and prevention of coronary graft failure. Circulation 2017; 136: 1749–1764.
9. Chowdhury UK, Aireb B, Mishra PK, et al. Histopathology and morphometry of radial artery conduits: basic study and clinical application. Ann Thorac Surg 2004; 78: 1614–1621.
10. Kaufer E, Factor SM, Frame R, et al. Pathology of the radial and internal thoracic arteries used as coronary artery bypass grafts. The Ann Thorac Surg 1997; 63: 1118–1122.
11. Nicolosi AC, Pohl LL, Parsons P, et al. Increased incidence of radial artery calcification in patients with diabetes mellitus. J Surg Res 2002; 102: 1–5.
12. Moon KW, Kim JH, Yoo KD, et al. Evaluation of radial artery atherosclerosis by intravascular ultrasound. Angiology 2013; 64: 73–79.
13. Prati F, Guagliumi G, Mintz GS, et al. Expert review document part 2: methodology, terminology and clinical applications of optical coherence tomography for the assessment of interventional procedures. Eur Heart J 2012; 33: 2513–2520.
14. Brown EN, Burris NS, Gu J, et al. Thinking inside the graft: Applications of optical coherence tomography in coronary artery bypass grafting. J Biomed Opt 2007; 12: 051704.
15. American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2021. Diabetes Care 2021; 44: S15–S33.
16. Homigberg MC, Zekavat SM, Pirruccello JP, et al. Cardiovascular and kidney outcomes across the glycemic spectrum: insights from the UK Biobank. J Am Coll Cardiol 2021; 78: 453–464.
17. Tearney GI, Regar E, Akasaka T, et al. Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: A report from the international working group for intravascular optical coherence tomography standardization and validation. J Am Coll Cardiol 2012; 59: 1058–1072.
18. Zhang S, Dai J, Jia H, et al. Non-culprit plaque characteristics in acute coronary syndrome patients with raised hemoglobinA1c: An intravascular optical coherence tomography study. Cardiovascular Diabetology 2018; 17: 90.
19. Yonetsu T, Kakuta T, Lee T, et al. Assessment of acute injuries and chronic intimal thickening of the radial artery after transradial coronary intervention by optical coherence tomography. Eur Heart J 2010; 31: 1608–1615.
20. Gao X, Song J, Watase H, et al. Differences in carotid plaques between symptomatic patients with and without diabetes mellitus. Arvb 2019; 39: 1234–1239.
21. Schalkwijk CG and Stehouwer CD. Vascular complications in diabetes mellitus: The role of endothelial dysfunction. Clin Sci (Lond) 2005; 109: 143–159.
22. Gursoy M, Guzel E, Erturkuner P, et al. Electron microscopic comparison of radial artery grafts in non-diabetic and diabetic coronary bypass patients. J Card Surg 2016; 31: 410–415.
23. McNeely MJ, McClelland RL, Bild DE, et al. The association between A1C and subclinical cardiovascular disease: The multi-ethnic study of atherosclerosis. *Diabetes Care* 2009; 32: 1727–1733.

24. Vukovic P, Peric M, Radak S, et al. Preoperative insight into the quality of radial artery grafts. *Angiology* 2017; 68: 790–794.

25. Stahli BE, Caduff RF, Greutert H, et al. Endothelial and smooth muscle cell dysfunction in human atherosclerotic radial artery: Implications for coronary artery bypass grafting. *J Cardiovasc Pharmacol* 2004; 43: 222–226.

26. Brown EN, Burris NS, Kon ZN, et al. Intraoperative detection of intimal lipid in the radial artery predicts degree of postoperative spasm. *Atherosclerosis* 2009; 205: 466–471.

27. Xiong R, He L, Du X, et al. Impact of diabetes mellitus and hemoglobin A1c level on outcomes among Chinese patients with acute coronary syndrome. *Clin Cardiol* 2020; 43: 723–731.

28. Cosentino F, Grant PJ, Aboyans V, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. *Eur Heart J* 2019; 41: 255–323.

29. Kassimis G, Bourantas CV, Tushar R, et al. Percutaneous coronary intervention vs. cardiac surgery in diabetic patients. Where are we now and where should we be going?. *Hellenic J Cardiol* 2017; 58: 178–189.

30. Reis JP, Allen NB, Bancks MP, et al. Duration of diabetes and prediabetes during adulthood and subclinical atherosclerosis and cardiac dysfunction in middle age: The CARDIA Study. *Diabetes Care* 2018; 41: 731–738.

31. Sucato V, Novo G, Evola S, et al. Coronary microvascular dysfunction in patients with diabetes, hypertension and metabolic syndrome. *Int J Cardiol* 2015; 186: 96–97.

32. Herrmann J. Coronary vasa vasorum neovascularization precedes epicardial endothelial dysfunction in experimental hypercholesterolemia. *Cardiovascular Res* 2001; 51: 762–766.

33. Kogo T, Hiro T, Kitano D, et al. Macrophage accumulation within coronary arterial wall in diabetic patients with acute coronary syndrome: a study with in-vivo intravascular imaging modalities. *Cardiovascular Diabetology* 2020; 19: 135.

34. Shah AS, Dolan LM, Kimball TR, et al. Influence of duration of diabetes, glycemic control, and traditional cardiovascular risk factors on early atherosclerotic vascular changes in adolescents and young adults with type 2 diabetes mellitus. *J Clin Endocrinol Metab* 2009; 94: 3740–3745.

35. Rossello X, Raposeiras-Roubin S, Oliva B, et al. Glycated hemoglobin and subclinical atherosclerosis in people without diabetes. *J Am Coll Cardiol* 2021; 77: 2777–2791.

36. Xu M, Zhang M, Xu J, et al. The independent and add-on values of radial intima thickness measured by ultrasound biomicroscopy for diagnosis of coronary artery disease. *Eur Heart J Cardiovasc Imaging* 2019; 20: 889–896.

37. Myredal A, Osika W, Li Ming G, et al. Increased intima thickness of the radial artery in patients with coronary heart disease. *Vasc Med* 2010; 15: 33–37.

38. Koganti S, Kotecha T and Rakhit RD. Choice of intracoronary imaging: When to use intravascular ultrasound or optical coherence tomography. *Interv Cardiol* 2016; 11: 11–16.

39. Kurihara O, Thondapu V, Kim HO, et al. Comparison of vascular response to statin therapy in patients with versus without diabetes mellitus. *Am J Cardiol* 2019; 123: 1559–1564.

### Appendix

**Abbreviations and acronyms**

- ACS, acute coronary syndrome
- CABG, coronary artery bypass grafting
- DM, diabetes mellitus
- eGFR, estimated glomerular filtration rate
- FCT, fibrous cap thickness
- IEI, intimal eccentricity index
- IMR, intima-media ratio
- IVUS, intravascular ultrasound
- MIT, maximum intimal thickness
- NGM, normal glucose metabolism
- OCT, optical coherence tomography
- PDM, prediabetes
- RA, radial artery
- ROC, receiver-operating characteristic